Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and Alkermes (ALKS) with bull...

Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)

Alkermes ( ($ALKS) ) has issued an announcement. At its annual general meeting on May 20, 2026, Alkermes shareholders approved amendments to the co...

Alkermes Shareholders Approve Amended Stock Incentive Plan

Alkermes plc ($ALKS) announced an update on their ongoing clinical study. The Brilliance NT1 Study 304 is a phase 3 trial run by Alkermes, Inc. to ...

Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) ...

Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Harmony Biosciences Holdings (HRMY), Maravai Lifes...

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Maravai Lifesciences Holdings (MRVI) and Alkermes (ALKS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS). ...

Analysts Offer Insights on Healthcare Companies: Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS)

Alkermes plc ($ALKS) announced an update on their ongoing clinical study. The Brilliance NT2 Study 303 is a phase 3 trial from Alkermes, Inc. that ...

Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Alkermes today and set a price target of $43.00. According to TipRanks, Tsao is a ...

H.C. Wainwright Sticks to Its Hold Rating for Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Tenaya Therapeutics (TNYA) with ...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Idexx Laboratories (IDXX) with b...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Baxter International (BAX) with ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$37.35	+1.49%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALKS	$37.35	+1.5%	1.12M
3
4
5
6

ALKS

ALKS

Get Alkermes plc Data in Excel

Get Alkermes plc Data in Excel